

Diabetic retinopathy progression associated with haplotypes of two VEGFA SNPs rs2010963 and rs699947

Haider Ali Alnaji, Rabab Omran, Aizhar H. Hasan & Mohammed Qasim Al Nuwaini

To cite this article: Haider Ali Alnaji, Rabab Omran, Aizhar H. Hasan & Mohammed Qasim Al Nuwaini (2023) Diabetic retinopathy progression associated with haplotypes of two VEGFA SNPs rs2010963 and rs699947, Egyptian Journal of Basic and Applied Sciences, 10:1, 123-134, DOI: 10.1080/2314808X.2022.2157124

To link to this article: <https://doi.org/10.1080/2314808X.2022.2157124>



© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 19 Dec 2022.



Submit your article to this journal [↗](#)



View related articles [↗](#)



View Crossmark data [↗](#)

Diabetic retinopathy progression associated with haplotypes of two VEGFA SNPs rs2010963 and rs699947

Haider Ali Alnaji ^{a,b}, Rabab Omran^b, Aizhar H. Hasan^b and Mohammed Qasim Al Nuwaini^c

^aMedical Laboratory Technology Department, College of Medical Technology, the Islamic University, Najaf, Iraq; ^bBiology Department, College of Science, Babylon University, Babylon, Iraq; ^cSurgery Department, College of Medicine, Jaber Ibn Hayan University, Najaf, Iraq

ABSTRACT

Diabetes-related retinopathy (DR) is one of the sight-threatening diseases. The present case-control study screened 134 patients with type 2 diabetes and 36 healthy ones without diabetes. The genotyping of SNPs rs2010963 and rs699947 of the VEGF gene were done by tetra primers ARMS-PCR. The mutant GG genotype of rs2010963 was significantly associated with DR (OR = 10.29; 95% CI = 2.20–59.06; $p = 0.004$). No significant associations existed between patients with DR and those with NDR or controls in the genotype or allele frequencies of rs699947 polymorphism. The haplotype analysis for rs2010963 and rs699947 shows the CG haplotype was significantly different between DR and NDR OR 2.0 (95% CI: 1.02–3.93), $p = 0.043$. and between DR and control OR 2.42 (95% CI: 1.2–4.65), $p = 0.0108$. The two SNPs showed moderate Linkage disequilibrium (LD) between DR and control, $D' = 0.64$ also, moderate LD between DR cases and NDR, $D' = 0.75$. No significant importance for rs699947 SNP with diabetic retinopathy. The 2010963 SNP in the VEGF gene is associated with the risk of NPDR and PDR. The findings also suggest a moderate LD in the two SNPs and their CG haplotype associated with DR progression.

ARTICLE HISTORY

Received 11 August 2022
Accepted 07 December 2022
Published online 10
December 2022

KEYWORDS

Haplotype; VEGF gene;
diabetic retinopathy;
rs2010963; rs699947

Introduction

Diabetes mellitus is a widespread disease associated with high morbidity rates [1,2]. Diabetes results in various consequences, classified as macrovascular (in a large blood vessel) problems, such as heart disease and stroke, and microvascular (in a small blood vessel) diseases, such as kidney disease. Diabetic retinopathy (DR), a microvascular complication of diabetes, is the leading cause of vision loss among the general population in different countries, notably among the working-age population and the elderly [3,4]. The disease of DR occurs due to damage to the retina as a consequence of

diabetic mellitus complications that lead to permanent damage to the eyes and sometimes even vision loss [5]. About 415 million individuals across the globe were diagnosed with diabetes in 2015, with estimates indicating that the number would increase to 642 million by the year 2040 [6]. Due to the rise in the number of individuals with diabetes and the increased duration of the disease, diabetic retinopathy, and eye disease are growing globally [7,8].

Diabetic Retinopathy (DR) is a leading cause of blindness. DR mutilates a diabetic patient's retinal blood vessels. The DR is classified into two main subtypes: non-proliferative diabetic

CONTACT Haider Ali Alnaji Hgeoda995@gmail.com Medical Laboratory Technology Department, College of Medical Technology, the Islamic University, Najaf, Iraq

retinopathy disease (NPDR) and proliferative diabetic retinopathy disease (PDR) [9]. During the early stages, the disease is known as NPDR, which is classified into three subcategories: mild, moderate, and severe. One microaneurysm (MA), a tiny red dot on the terminal of blood vessels, is seen in the mild stage. The MAs ascend to a deeper layer of the retina in the Moderate stage and create a flame-shaped hemorrhage. The severe stage is characterized by more than 20 intraretinal hemorrhages in each of the four quadrants, with obvious venous bleeding and significant intraretinal microvascular changes in the affected retina. When DR progresses to the advanced stage of the disease, it results in neovascularization, the natural development of new blood vessels in the form of functioning microvascular networks that grow on the surface of the retina, and the disease known as PDR [10].

The VEGF (VEGF) gene is located on chromosome 6 p 21.1. About 4 kb, the size of its coding region. The VEGF gene has eight exons that may be combined in different ways to produce a wide variety of mRNAs via alternative splicing. This gene's polymorphism exceeds the 150 SNPs in exons or promoters [11]. These SNPs are primarily clustered in the VEGF gene's promoter and 5'-UTR [12]. The 5'-UTR has many different binding sites for transcription factors, and the polymorphisms in this region cause gene expression changes [13]. This study aimed to investigate whether DR patients had an association with genotypes of two SNPs in the VEGF gene and whether a specific set of variants of these SNPs inherited together.

Methods

Subject. Recruit 134 patients with diabetes and 36 healthy controls in a case-control study. The ophthalmologist evaluated the patient's eyes, sought the presence of any signs of DR, and grouped them into 64 subjects with NPDR, 39 subjects with PDR, and 31 diabetic patients without retinopathy (NDR). The sociodemographic

characteristics of patients were presented in our previous study [14].

Selection criteria. Participants included those 18 years or older with a medical history consistent with type 2 diabetes under the criteria of the World Health Organization in its 2019 categorization standards [15]. One or two eyes with any signs of the DR were included. Individuals affected by inflammatory retinal disorders (uveitis, retinal vasculitis) and all type 1 diabetes were excluded. Eight samples were excluded from statistical analysis because they did not give any variation; it is suspected they showed genotypes differently for rs2010963 (C > T instead of C > G).

Genotyping. Genomic DNA was extracted from whole blood in EDTA tubes using G-spin™ Total DNA Extraction Mini Kit (iNtRON Biotechnology, Korea) and stored at -20°C in the biotechnology laboratory of Babylon University until the genotyping. The genotyping of the SNPs in the study were tetra primers ARMS-PCR technique. In brief, the outer primers of rs2010963 and rs699947 SNPs generate the confirmative amplicon for the 5' UTR and promoter region where the SNPs resides. The inner reverse primers were designed for the mutant allele by mismatching the 3' end of the primer. Also, the third nucleotide of the 3' end was mismatched to increase the specificity. The PCR steps were as follows: 40 cycles of denaturation at 95°C for 35 s and annealing at 65°C decreased gradually every cycle to reach the lowest annealing at 58°C for 40 s and 72°C for extension and final extension for 40 s and 7 min respectively. The PCR cycles are preceded by initial denaturation at 95°C for 2 min for activation. Followed by agarose gel electrophoresis (2% and 75 V) for 1 hour. The SNPgen® tool was used to design rs2010963 primers, whereas rs699947 primers were obtained from an Elfaki et al. study [16], as shown in Table 1.

Statistical analysis. The SPSS version 26.0 for Windows was used (Chicago, IL, USA). Genotype and allele frequency of VEGF polymorphisms were compared between the control group

Table 1. Primers utilized in the detection of SNPs by the tetra primers ARMS-PCR.

SNP	Primer direction	Primer sequence*	Allele	Tm (°C)	Ta (°C)	Amplicon (bp)
rs2010963	FO	CGACGGCTTGGGAGATTGCTCTAC		71	58	273
	RO	GGCGGTGTCTGTCTGTCTGCCGT		71		
	FI	GCGTGCGAGCAGCGAATGC	C	71		
	RI	CAGTCACTCACTTTGCCCTGACC	G	71		
rs699947 [‡]	FO	CCTTTCTCATAAAGGCCTTAG		65	58	353
	RO	AGGAAGCAGCTTGGAAAAATTC		65		
	FI	TAGGCCAGACCTGGCAA	A	65		
	RI	GTCTGATTATCCACCCAGATCG	C	65		

*The mismatches of the allele-specific primers are emphasized in bold

[‡]primers are obtained from [16]. Abbreviations: FI: forward inner, FO: forward outer, RI: reverse inner, RO: reverse outer, SNP: single nucleotide polymorphisms, Ta: melting temperature, Ta annealing temperature.

and the case groups using the Chi-square test [17]. The binary and multinomial logistics were used to estimate the risk allele and genotype associated with DR, NPDR, and PDR. The haploview 4.2 (Broad Institute) program was used to calculate the haplotype frequencies of the VEGF rs2010963 and rs699947 SNPs and to build linkage disequilibrium (LD).

Results

The genotyping of rs2010963 and rs699947 using the tetra primer-ARMS PCR. The bands were presented as follows the band of the C allele is 140 bp., and the G allele band is 177 bp. The heterozygous (CG) is shown in the presence of the two bands (140 bp. and 177 bp.) **Figure 1** for rs2010963. The bands of rs699947 were presented as follows the band of the A allele is 243 bp. The C allele band is 149 bp. The heterozygous (AC) is shown in the presence of the two bands (149 bp. and 243 bp.) **Figure 2**.

The genotypic and allelic frequencies of rs2010963 in the healthy control (HC), NDR, and DR groups are detailed in **Table 2**. The genotype distribution of rs2010963 was in

Hardy-Weinberg equilibrium (HWE) in the control group and cases groups using Yate's correction (p -value ≥ 0.054). The Chi-square test results demonstrated that the frequencies of genotypes and alleles among study groups were statistically significant, with p -value = 0.027 and 0.024, respectively. The results revealed that the heterozygote genotype (CG) has a higher frequency among all of the controls, NDR, NPDR, and PDR; the lowest frequency is for the CC genotype. The G Allele was a higher frequency in case groups; in contrast, the C allele was a higher frequency than the G allele in the control group ($P = 0.024$). The genotypic and allelic frequencies of rs699947 in the HC, NDR, and DR groups are detailed in **Table 2**. Neither the NPDR nor the PDR groups showed any significant differences in genotype or allele frequency for the rs699947 polymorphism compared to the control or NDR groups. The C allele frequency among case groups was 64.8% and 70.5%, whereas in the controls and NDR groups was 63.6% and 56.9%, respectively; thus, no significant differences were found between controls and cases regarding the C allele.




Figure 1. Agarose gel electrophoresis for the tetra primer-ARMS PCR product for genotyping rs2010963 SNP. (75 V for 60 min, M: DNA marker 50–500 bp, 2% Agarose).




Figure 2. Agarose gel electrophoresis of the tetra primer-ARMS PCR for genotyping rs699947 SNP (75 V for 60 min, M: DNA marker 50–500 bp, 2% Agarose).

The VEGF polymorphisms were selected for logistic regression analysis for the genetic association study. First; we made a binary logistic regression analysis of the comparison between control and DR subjects and NDR and DR subjects; for rs2010963, the results revealed that the homozygous GG genotype of minor alleles was significantly associated with DR (OR = 10.29; 95% CI = 2.20–59.06; $p = 0.004$). No statistically significant association with DR for the heterozygous CG genotype (Table 3). The second is a multinomial logistic regression analysis between groups of DR (NPDR and PDR), which once compared with the controls and then for the NDR group. The analysis showed that minor alleles (GG) were also strongly associated with NPDR and PDR (OR = 6.33; 95% CI = 1.20–33.39; $p = 0.030$) and (OR = 34; 95% CI = 2.9–392.94; $p = 0.005$) respectively (Tables 3 and 4). However, the heterozygous

CG genotype was unrelated to NPDR or PDR state (Table 4). In contrast, for rs699947, the heterozygous AC and homozygous (AA & CC) genotypes in binary logistic regression and multinomial logistic regression were statistically insignificant in DR status, and subtypes of DR (NPDR & PDR) Tables 3 and 4, respectively.

Moreover, in the case of rs2010963, the GG genotype and recessive model (CC+CG vs. GG) frequencies were significantly higher in the DR compared with controls (OR = 0.10; 95% CI = 0.02–0.46; $p = 0.002$) and (OR = 5.63; 95% CI = 1.75–18.38; $p = 0.003$), respectively. Interestingly, when analyzing the association between groups of DR (NPDR and PDR) with controls and NDR, the dominant model (CC vs. CG+GG) was statistically significant only with PDR (OR = 8.44; 95% CI = 1.20–99.07; $p = 0.026$). In contrast, the recessive model (CC +CG vs. GG) was associated with NPDR and PDR

Table 2. Distribution of Alleles and genotypes of rs2010963 and rs699947 between Controls, NDR, NPDR and PDR.

SNP	Allele/ Genotype	HC(%)	NDR(%)	NPDR(%)	PDR(%)	X2	df	P-value
rs2010963	C	36(54.5)	24(41.4)	48(39.3)	23(29.5)	9.42	3	0.024
	G	30(45.5)	34(58.6)	74(60.7)	55(70.5)			
	CC	6(18.2)	5(17.2)	6(9.8)	1(2.6)	14.3	6	0.027
	CG	24(72.7)	14(48.3)	36(59.0)	21(53.8)			
	GG	3(9.1)	10(34.5)	19(31.1)	17(43.6)			
HWE \downarrow		0.054	0.98	0.065	0.07			
rs699947	A	24(36.4)	25(43.1)	43(35.2)	23(29.5)	2.72	3	0.437
	C	42(63.6)	33(56.9)	79(64.8)	55(70.5)			
	AA	2(6.1)	6(20.7)	7(11.5)	4(10.3)	6.66	6	0.354
	AC	20(60.6)	13(44.8)	29(47.5)	15(38.5)			
	CC	11(33.3)	10(34.5)	25(41.0)	20(51.3)			
HWE \downarrow		0.075	0.64	0.75	0.64			

Abbreviations df: Degree of freedom, HC: Healthy control, HWE: Hardy–Weinberg equilibrium p -value. \downarrow if < 0.05 – not consistent with HWE, NDR: Non diabetic retinopathy, NPDR: Nonproliferative diabetic retinopathy, PDR: Proliferative diabetic retinopathy, SNP: single nucleotide polymorphisms, X2: Chi-square

Table 3. Binary Logistic Regression for rs2010963 & rs699947 SNP between Controls, NDR and DR.

SNP	Genotype	Control	NDR	DR	OR(95%CI)	P-value
rs2010963	CC	6	5	7	Reference	
	CG	24	14	57	2.04(0.60–6.76)a 0.34(0.09–1.31)b	0.242a 0.104b
	GG	3	10	36	10.29(2.20–59.06)a 0.39(0.10–1.55)b	0.004a 0.169b
rs699947	AA	2	6	11	1.34(0.30–9.49)a 2.45(0.71–8.2)b	0.724a 0.145b
	AC	20	13	44	0.54(0.23–1.23)a 1.33(0.53–3.4)b	0.150a 0.545b
	CC	11	10	45	Reference	

^acomparison between controls and DR, ^b comparison between NDR and DR

Abbreviations CI: confidence interval, DR: Diabetic retinopathy, NDR: Non diabetic retinopathy, OR: odds ratio, SNP: single nucleotide polymorphisms.

Table 4. Multinomial Logistic Regression for rs2010963 & rs699947 SNP between Controls, NDR, NPDR and PDR.

Gene	SNP	Genotype	OR(95%CI)	P-value	
VEGF	rs2010963	CC	Reference		
		CG	1.50(0.43–5.20)a 5.25(0.58–47.22)b 2.14(0.56–8.17)c 7.50(0.79–71.23)d	0.523a 0.139b 0.264c 0.079d	
		GG	6.33(1.20–33.39)a 34(2.9–392.94)b 1.58(0.39–8.16)c 8.50(0.87–83.49)d	0.030a 0.005b 0.524c 0.066d	
		rs699947	AA	1.54(0.275–8.64)a 1.10(0.173–6.99)b 0.47(0.13–1.74)c 0.33(0.076–1.46)d	0.624a 0.920b 0.256c 0.144d
				AC	0.64(0.257–1.58)a 0.41(0.15–1.12)b 0.89(0.33–2.38)c 0.58(0.19–1.67)d
			CC	Reference	

^acomparison between controls and NPDR, ^b comparison between controls and PDR, ^c comparison between NDR and NPDR, ^d comparison between NDR and PDR. Abbreviations CI: confidence interval, OR: odds ratio, SNP: single nucleotide polymorphisms.

subjects ($p = 0.016$ and 0.001 , respectively) (Tables 5 and 6). In contrast, for rs699947, the comparisons between DR status and subtypes of DR (NPDR & PDR) with controls regarding dominant, recessive, codominant, and heterozygous models revealed similar results (p -value > 0.05) for all models Tables 5 and 6. Thus, our samples have no significant importance for this SNP with diabetic retinopathy.

Haplotype analysis and linkage disequilibrium. The haplotype analysis results and the Linkage disequilibrium pattern (LD) between VEGF polymorphisms (rs2010963 and

rs699947) are shown in Tables 7 and 8. and Figures 3 and 4, respectively. The predicted haplotypes with frequencies ≥ 0.03 were compared between the DR, NDR, and control groups. The frequency of CG haplotype was statistically significant between DR and NDR (OR = 2.0; 95% CI = 1.02–3.93; $p = 0.043$), and also there were significant differences between DR and controls (OR = 2.42; 95% CI = 1.2–4.65; $p = 0.0108$). The CC haplotype appears to have significant differences between DR and control groups only (OR = 0.56; 95% CI = 0.33–0.99; $p = 0.0479$) (Tables 7 and 8). Pairwise LD

Table 5. Association of Different Genetic Models for rs2010963 & rs699947 SNP between Controls, NDR, and DR.

SNP	Genotype	Control	NDR	DR	OR(95%CI)	P-value
rs2010963	Dominant					
	CC	6	5	7	2.95(0.86–8.91)a	0.061a
	GG+CG	27	24	93	2.77(0.89–9.05)b	0.095b
	Recessive					
	CG+CC	30	19	64	5.63(1.75–18.38)a	0.003a
	GG	3	10	36	1.07(0.46–2.58)b	0.881b
	Codominant					
	CG	24	14	57	2.01(0.83–4.74)a	0.108a
	GG+CC	9	15	43	0.70(0.31–1.59)b	0.406b
	Homozygotic model					
rs699947	GG	3	10	36	0.10(0.02–0.46)a	0.002a
	CC	6	5	7	0.39(0.11–1.45)b	0.160b
	Dominant					
	AA	2	6	11	0.52(0.111–2.43)a	0.407a
	AC+CC	31	23	89	2.11(0.68–5.91)b	0.174b
	Recessive					
	AC+AA	22	19	55	1.64(0.71–3.56)a	0.239a
	CC	11	10	45	1.56(0.68–3.71)b	0.313b
	Codominant					
	AC	20	13	44	1.96(0.87–4.41)a	0.098a
AA+CC	13	16	56	1.03(0.44–2.32)b	0.937b	
Homozygotic model						
CC	11	10	45	1.34(0.27–6.76)a	0.724a	
AA	2	6	11	0.41(0.13–1.52)b	0.138b	

^acomparison between controls and DR, ^b comparison between NDR and DR.

Abbreviations CI: confidence interval, DR: Diabetic retinopathy, NDR: Non diabetic retinopathy, OR: odds ratio, SNP: single nucleotide polymorphisms.

parameter D' was 0.75 with $r^2 = 0.17$ for DR and NDR groups. In contrast, D' was 0.64 with $r^2 = 0.14$ for DR and control groups. The findings suggest a moderate LD in two SNPs (rs2010963 and rs699947).

Discussion

In this study, we looked at the possibility that VEGF polymorphisms are linked to the existence of DR in a well-defined group of Iraqi patients with type 2 diabetes. VEGF serves as the primary regulator in both normal and abnormal vascular development. It has the potential to enhance retinal vascular permeability, destroy the blood-retinal barrier, and generate new blood vessels in DR, all of which are directly linked to the emergence and progression of the disease [18]. The VEGF polymorphism (rs2010963) was the one that received the most attention from researchers. Previous studies have demonstrated that rs2010963 is one of many SNPs associated

with increased or decreased VEGF protein synthesis and may alter protein conformation [19]. We've already shown solid evidence linking VEGF SNP rs2010963 to DR severity or existence. The rs2010963 locate on 5' UTR of the VEGF gene; in the 5'UTR of the VEGF gene, the G + C content (up to 83%) upstream of the transcription start point is relatively high. The 5'-untranslated region of the VEGF gene (5'UTR) plays a key part in VEGF production. Change in the sequence of this region is thought to be linked to alterations in protein expression of the VEGF gene, which in turn may increase the risk of developing retinopathy [20,21] as well as NPDR in the Asian population [22]. Yang et al. concluded that rs2010963 was a risk factor for PDR in most groups but not Caucasians, where no link was found between rs2010963 and PDR development [23]. According to our findings, those with the GG genotype had a higher probability of developing PDR than those with the CC genotype. Compared with other studies, CG lowered the risk of PDR [24]. On the other hand,

Table 6. Association of Different Genetic Models for rs2010963 & rs699947 SNP between Controls, NDR, NPDR, and PDR.

SNP	Genotype	HC	NDR	NPDR	PDR	OR(95%CI)	P-value	
rs2010963	Dominant CC	6	5	6	1	2.04(0.56–7.47)a 8.44(1.20–99.07)b 0.50(0.20–1.80)c	0.247a 0.026b 0.30c	
		GG+CG	27	24	55	38	0.13(0.01–1.1)d	0.035d
		Recessive CG+CC	30	19	42	22	4.52(1.22–15.31)a 7.73(2.15–26.61)b 1.2(0.5–2.95)c	0.016a 0.001b 0.75c
	GG Codominant CG	3	10	19	17	0.68(0.3–1.9)d	0.45d	
		24	14	36	21	1.85(0.73–4.35)a 2.29(0.86–6.07)b 1.50(0.60–3.60)c	0.187a 0.099b 0.34c	
	GG+CC Homozygotic model GG	9	15	25	18	1.25(0.50–3.40)d	0.65d	
		3	10	19	17	0.16(0.04–0.82)a 0.03(0.002–0.29)b 1.60(0.38–5.90)c	0.022a 0.001b 0.52c	
	rs699947	CC Dominant AA	6	5	6	1	8.5(1.12–104.9)d	0.04d
			2	6	7	4	0.49(0.10–2.55)a 0.56(0.10–2.58)b 2.0(0.563–6.35)c	0.394a 0.521b 0.245c
		AC+CC Recessive AC+AA	31	23	54	35	2.28(0.63–7.70)d	0.229d
22			19	36	19	1.39(0.57–3.36)a 2.11(0.84–5.21)b 1.32(0/51-3.51)c	0.466a 0.125b 0.554c	
CC Codominant AC		11	10	25	20	2.0(0.75–5.15)d	0.168d	
		20	13	29	15	1.69(0.73–3.79)a 2.46(0.99–6.68)b 0.89(0.38–2.26)c	0.226a 0.061b 0.81c	
AA+CC Homozygotic model CC		13	16	32	24	1.30(0.476–3.56)d	0.598d	
		11	10	25	20	1.54(0.32–8.19)a 1.10(0.21–6.49)b 0.47(0.129–1.61)c	0.622a 0.920b 0.251c	
AA		2	6	7	4	0.33(0.09–1.32)d	0.136d	

^acomparison between controls and NPDR, ^b comparison between controls and PDR, ^c comparison between NDR and NPDR, ^d: comparison between NDR and PDR. Abbreviations: Non diabetic retinopathy, NPDR: Nonproliferative diabetic retinopathy, PDR: Proliferative diabetic retinopathy, SNP: single nucleotide polymorphisms, X2: Chi-square

Table 7. Haplotyping of rs2010963 and rs699947 of VEGF among DR and NDR.

Haplotype	Frequency	NDR	DR	OR(95%CI)	X2	p-value
C-C	0.34	0.366	0.327	0.85(0.46–1.58)	0.30	0.581
A-G	0.32	0.383	0.302	0.70(0.38–1.29)	1.36	0.244
C-G	0.311	0.203	0.343	2.0(1.02–3.93)	4.10	0.043
A-C	0.03	0.048	0.028	0.56(0.15–2.13)	0.57	0.449

Abbreviations CI: confidence interval, DR: Diabetic retinopathy, NDR: Non diabetic retinopathy, OR: odds ratio, X2: Chi-square.

a study by Fan showed that gene polymorphisms such

as rs2010963 have been strongly linked with Recent meta-analysis findings indicated that rs2010963 was associated with PDR in the

overall population VEGF protein in the blood [25]. The VEGF protein is a potent angiogenic agent in various diseases. It has been established that elevated serum and vitreous levels of VEGF in the presence of retinopathy are

Table 8. Haplotyping of rs2010963 and rs699947 of VEGF among DR and control.

Haplotype	Frequency	DR	Controls	OR(95%CI)	X2	p-value
C-C	0.354	0.454	0.321	0.56(0.33–0.99)	3.852	0.0497
A-G	0.29	0.273	0.296	1.12(0.61–2.04)	0.134	0.7145
C-G	0.307	0.182	0.349	2.42(1.2–4.65)	6.491	0.0108
A-C	0.048	0.091	0.034	0.36(0.13–1.15)	3.552	0.0595

Abbreviations: CI: confidence interval, DR: Diabetic retinopathy, OR: odds ratio, X2: Chi-square.




Figure 3. Linkage disequilibrium (LD) of rs2010963 and rs699947 SNPs in DR and NDR. (a) The pairwise LD between SNPs, using D' (red color) value. (b) The pairwise LD between SNPs, using r^2 (gray color) value, LD is represented by D' or r^2 multiplied by 100.

closely associated with proliferative diabetic retinopathy [26]. A study from Egypt explored the association between rs699947 SNP and the susceptibility of DR, and it found no significant association between them. This result is consistent with our findings [27]. Different studies also revealed no association between the presence of rs699947 SNP and the risk of DR [28]. In a previous meta-analysis, the rs699947 in Asian individuals with type 2 diabetes are more likely to be associated with DR but not in white people [29]. While a meta-analysis from China recognizes the reverse association that rs699947 polymorphism is strongly connected with DR after adjusting for outliers, rs2010963 polymorphism may not be linked to DR [30]. Different meta-analyses on rs2010963; one revealed an association while the other did not [31,32].

In contrast, many others showed a positive association of rs699947 SNP with the susceptibility of DR [12,13,33]. A recent meta-analysis demonstrated that rs699947 might be implicated in the emergence and progression of DR [22]. Numerous studies have discovered an association between various genetic polymorphisms and DR, whereas others have failed to do so [34]. This outcome discrepancy might be due to a sample size disparity and clinical or methodological heterogeneity, and sampling of allele inheritance but not genotype. The degree of heterogeneity is likely influenced by several factors, including ethnicity, environmental factors, and social relationships that govern the cross-mating between families. Also, it might be that these polymorphisms convey sex depending on where there are different proportions of males/females in various studies; the discrepancy




Figure 4. Linkage disequilibrium (LD) of rs2010963 and rs699947 SNPs in DR and control. (a)The pairwise LD between SNPs, using D' (red color) value, (b)The pairwise LD between SNPs, using r^2 (gray color) value, LD is represented by D' or r^2 multiplied by 100.

occurs. However the two SNPs (rs699947 & rs2010963) among DR patients revealed no association with gender, and since majority of included studies did not report the association of the genotypes of the rs699947 & rs2010963 SNPs with gender, we are unable to perform the further analysis. Only few studies found that sex may be a risk factor for DR, but not polymorphisms [35,36]. Yet we drew in our account a conclusion; the two SNPs (rs699947 & rs2010963) among NPDR and PDR need to be studied further to identify the link between the two.

The findings suggest a moderate LD in two SNPs (rs2010963 and rs699947). The rs699947, as mentioned early in the study, it was observed to have no significant association with DR; however, the C allele shared with the G allele of rs2010963; both alleles are minor alleles (mutant) and contributed significantly >2 folds to DR progression. Thus, it is valuable to measure the LD, which confers a piece of more information if statistical genetics fails to find an association. LD occurs when nonrandom

gametic alleles are associated at various loci in a population [37]. The haplotype has an effect that differs from genotypes on disease, and the locus is still of clinical importance even though there is no link between genotype and clinical condition [38]. The VEGF gene SNPs located at the promoter region and 5' UTR and

the presence of the CG haplotype association confer upregulation or downregulation of VEGF expression, eventually leads to worsen normal vision. A recent study shows different haplotypes (CD) from rs699947 and rs35569394 polymorphisms have a non-significant association with DR. Simultaneously, their alleles C and D have strong LD [33]. One explanation is differences in allele and genotype frequencies of SNPs on one side and, on the other, the differences between different studies. Also, the patterns of LD

are from each other have strong LD. The haplotype and LD are important for large-scale association-mapping studies [39]. unpredictable; two loci near each other might have weak LD, whereas loci of different SNPs that

are so far from each other have strong LD. The haplotype and LD are important for large-scale association mapping studies [40].

Conclusion

The GG genotype of rs2010963 in the VEGF gene had a higher probability of developing either NPDR or PDR. No significant importance for rs699947 SNP with diabetic retinopathy. The findings suggest a moderate LD in two SNPs (rs2010963 and rs699947) and their CG haplotype associated with DR progression by 2 folds.

Acknowledgments

We would like to thank Dr. Giyath Al-Deen Thegil Neamah for his kind words and moral support.

Disclosure statement

No potential conflict of interest was reported by the author(s).

ORCID

Haider Ali Alnaji  <http://orcid.org/0000-0002-6977-2928>

Abbreviations

CI: Confidence interval; DM: Diabetes mellitus DR: Diabetic retinopathy; HC: Healthy controls; HWE: Hardy–Weinberg equilibrium; MA: Microaneurysm; LD: Linkage disequilibrium; NDR: Non diabetic retinopathy; NPDR: Non-proliferative diabetic retinopathy; OR: Odds ratio; PDR: Proliferative diabetic retinopathy; SNPs: Single nucleotide polymorphisms; T-ARMS PCR: Tetra primer amplification refractory mutation system polymerase chain reaction; T1DM: Type 1 diabetes mellitus; T2DM: Type 2 diabetes mellitus; VEGF: Vascular endothelial growth factor; UTR: untranslated region.

Ethical approval

Ethical approval for this study was granted by the human ethics committee (IRB) at the University of

Kufa ((347/2021). we are following the ethical standards of the Helsinki Declaration.

References

- [1] Abdul JAKK, Kais Abdul Jaleel Duaibel AK, Alnaji HA, et al. The role of MCP-1 in the developments of diabetic nephropathy in patients with type 2 diabetes mellitus patients. *Int J Health Sci (Qassim)*. [Internet]. 2022 May 7 cited 2022 Jul 26;6(S2):8158–8166. Available from: <https://sciencescholar.us/journal/index.php/ijhs/article/view/7049>
- [2] Akkaj D, Al-Janahi FAA, Naji AM, et al. Glu298Asp polymorphism in exon 7 of the eNOS gene in foot ulcer of adult patients with type 2 diabetes. *AIP Conf Proc*. [Internet]. 2022 Jan 11 cited 2022 Jul 26;2386(1):020013. Available from: <https://aip.scitation.org/doi/abs/10.1063/5.0067092>
- [3] Ali Mezil BAA S. Complication of diabetes mellitus. *Ann Rom Soc Cell Biol* [Internet]. 2021 Mar 22 cited 2022 Oct 26;1546–1556. Available from : . <https://www.annalsofscb.ro/index.php/journal/article/view/1601>
- [4] Vaswani R, Shukla S, Acharya S. Pathophysiology of complication in diabetes mellitus. *J Pharm Res Int*. 2021 Dec 19;89–95. [10.9734/jpri/2021/v33i60A34459](https://doi.org/10.9734/jpri/2021/v33i60A34459).
- [5] Gadekallu TR, Khare N, Bhattacharya S, et al. Deep neural networks to predict diabetic retinopathy. *J Ambient Intell Humaniz Comput*. 2020;11:1–14.
- [6] Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes Res Clin Pract*. 2017;128:40–50.
- [7] Alnaji H, Alnuwaini MQ, Almulla AF. Low levels of postprandial C-peptide are clinically significant in non-proliferative diabetic retinopathy and diabetic macular oedema in Iraqi patients with type 2 diabetes. *Art Int J Health Sci* [Internet]. 2022 cited 2022 Jul 18; Available from. [10.53730/ijhs.v6n51.6785](https://doi.org/10.53730/ijhs.v6n51.6785) 8258–8267
- [8] Abdul Jaleel AK, Almulla AF, Alnaji HA, et al. Diabetes mellitus and non-proliferative diabetic retinopathy are accompanied by increase pro-inflammatory conditions indicated by a high blood-derived levels of monocyte chemoattractant protein-1 and interleukin-8. *Iran J War Public Health* [Internet]. 2022 cited 2022 Jul 25;14

- (2):203–210. Available from: <http://ijwph.ir/article-1-1165-en.html>
- [9] Memon WR, Lal B, Sahto AA. Diabetic retinopathy. *Prof Med J*. 2017;24(2):234–238.
- [10] Kavitha K. Incidence of retinopathy changes in new cases of diabetes mellitus type 2. 2013 cited 2022 Oct 26]; 2022 Oct 26: <http://repository-tnmgrmu.ac.in/3144/>
- [11] Koutras A, Kotoula V, Fountzilias G. Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer. *Pharmacogenomics*. 2015 Jan 1; 16(1):79–94.
- [12] Qayyum S, Afzal M, Naveed A. Association of vascular endothelial growth factor A gene (VEGFA) polymorphisms, rs699947 and rs1570360, with diabetic retinopathy and altered VEGF. 2020 cited 2022 Jul 5]; 2022 Jul 5: <https://www.researchsquare.com/article/rs-18816/latest.pdf>
- [13] Wijaya AR, Surudarma IW, Wihandani DM, et al. Polymorphisms of vascular endothelial growth factor—2578C/A rs699947 are risk factors for diabetic retinopathy in type-2 diabetes mellitus patients in Bali, Indonesia. *Biomedicine (Taipei)*. Internet]. 2021 cited 2022 Jul 5;11(2):11. Available from:;. /pmc/articles/PMC8824245/
- [14] Alnaji HA, Hassan AH, Omran R. Genetic polymorphism of AKR1B1 with diabetic retinopathy. *Int J Health Sci (Qassim)*. Internet]. 2022 May 25 cited 2022 Jul 26;6(53):8310–8315. Available from:;. <https://sciencescholar.us/journal/index.php/ijhs/article/view/7898>
- [15] Organization WH. Classification of diabetes mellitus. 2019 cited 2022 Oct 22]; 2022 Oct 22: https://apps.who.int/iris/handle/10665/325182?locale-attribute=ar&utm_source=transaction&utm_medium=email
- [16] Elfaki I, Mir R, Duhier FMA, et al. Clinical implications of MiR128, angiotensin I converting enzyme and vascular endothelial growth factor gene abnormalities and their association with T2D. *Curr Issues Mol Biol*. 2021, 43, 1859–1875 [Internet]. 2021 Nov 2 cited 2022 Jul 16;43(3):1859–1875. Available from:;. <https://www.mdpi.com/1467-3045/43/3/130/htm>
- [17] Alsadawi AA, Duabel AKKA J, Alnaji HA. Hepatitis C and il-6 with 174G/C gene polymorphism in β -thalassemia. *Int J Drug Delivery Technol*. 2019;9(4):617–622.
- [18] Wang H, Cheng JW, Zhu LS, et al. Meta-analysis of association between the –2578C/A polymorphism of the vascular endothelial growth factor and retinopathy in type 2 diabetes in Asians and caucasians. *Ophthalmic Res*. Internet]. 2014 cited 2022 Jul 4;52(1):1–8. Available from:
- [19] Sellami N, Ben LL, Turki A, et al. Association of VEGFA variants with altered VEGF secretion and type 2 diabetes: a case-control study. *Cytokine*. 2018 Jun 1;106:29–34.
- [20] Zhang S, Li Q, Yang M, et al. Relationship between the 5'UTR of vascular endothelial growth factor polymorphism and retinopathy of prematurity in Chinese premature newborns. *Int J Clin Exp Pathol Internet*. 2017 cited 2022 Jul 4;10(12):11695. Available from:;. /pmc/articles/PMC6966069/
- [21] Al-Abdullah AA, Kozak I. Toward better evidence: meta-analysis of vascular endothelial growth factor (VEGF) polymorphisms in retinopathy of prematurity. *Saudi J Ophthalmol Internet*. 2014 Oct 1 cited 2022 Jul 4;28(4):251. Available from:
- [22] Hu L, Gong C, Chen X, et al. Associations between vascular endothelial growth factor gene polymorphisms and different types of diabetic retinopathy susceptibility: a systematic review and meta-analysis. *J Diabetes Res*. 2021;2021:1–12.
- [23] Yang Q, Zhang Y, Zhang X, et al. Association of VEGF gene polymorphisms with susceptibility to diabetic retinopathy: a systematic review and meta-analysis. *Hormone Metab Res*. 2020 May 1; 52(5):264–279.
- [24] Jin H, Jiang D, Ding Z, et al. Association of four gene polymorphisms in Chinese Guangxi population with diabetic retinopathy in type 2 diabetic patients. *BMC Ophthalmol*. 2021. Internet]. cited 2022 Jul 5;21:383. Available from;(1):.
- [25] Fan XH, Wu QH, Li Y, et al. Association of polymorphisms in the vascular endothelial growth factor gene and its serum levels with diabetic retinopathy in Chinese patients with type 2 diabetes: a cross-sectional study. *Chin Med J (Engl)*. 2014;127(4):651–657.
- [26] Khan SZ, Ajmal N, Shaikh R. Diabetic retinopathy and vascular endothelial growth factor gene insertion/deletion polymorphism. *Can J Diabetes*. 2020 Apr 1; 44(3):287–291.
- [27] Fattah RAA, Eltanamly RM, Nabih MH, et al. Vascular endothelial growth factor gene polymorphism is not associated with diabetic retinopathy in egyptian patients. *Middle East Afr J Ophthalmol*. Internet]. 2016 Jan 1 cited 2022 Jul 5;23(1):75. Available from ;:

- [28] Shahin RMH, Abdelhakim MASE, Owid MESM, et al. A study of VEGF gene polymorphism in egyptian patients with diabetic retinopathy. *Ophthalmic Genetics*. Internet]. 2014 Dec 9 cited 2022 Dec 9;36(4):315–320.
- [29] Wang H, Cheng JW, Zhu LS, et al. Meta-analysis of association between the –2578C/A polymorphism of the vascular endothelial growth factor and retinopathy in type 2 diabetes in Asians and Caucasians. *Ophthalmic Res*. 2014 cited 2022 Oct 28;52 1:1–8. Internet]: Available from: <https://www.karger.com/Article/FullText/357110>
- [30] Lu Y, Ge Y, Shi Y, et al. Two polymorphisms (rs699947, rs2010963) in the VEGFA gene and diabetic retinopathy: an updated meta-analysis. *BMC Ophthalmol*. Internet]. 2013 Oct 16 cited 2022 Oct 28;13(1):1–9. Available from: <https://bmcophthalmol.biomedcentral.com/articles/10.1186/1471-2415-13-56>
- [31] Han L, Zhang L, Xing W, et al. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case-control studies. *J Diabetes Res*. 2014;2014:1–10.
- [32] Qiu M, Xiong W, Liao H, et al. VEGF – 634G>C polymorphism and diabetic retinopathy risk: a meta-analysis. *Gene*. 2013 Apr 15; 518 (2):310–315.
- [33] Rabbind Singh A, Gupta R, Shukla M, et al. Association of VEGFA promoter polymorphisms rs699947 and rs35569394 with diabetic retinopathy among North-Central Indian subjects: a case-control study. *Ophthalmic Genetics*. 2021;43(1);80–87. Internet]. cited 2021 Jul 5; Available from
- [34] Owyong M, Schwartz S. An update on the genetics of diabetic retinopathy. *RETINA TODAY* [Internet]. 2017 cited 2022 Oct 28]; 2022 Oct 28: https://assets.bmctoday.net/retinatoday/pdfs/0317RT_Cover_Scott.pdf
- [35] Varma R, Macias GL, Torres M, et al. Biologic risk factors associated with diabetic retinopathy: the los angeles latino eye study. *Ophthalmology*. 2007 Jul 1; 114 (7):1332–1340.
- [36] Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. *JAMA* [Internet]. 2010 Aug 11 cited 2022 Dec 2;304 (6):649–656. Available from:
- [37] Qanbari S. On the extent of linkage disequilibrium in the genome of farm animals. *Front Genet*. 2020 Jan 17; 10:1304
- [38] Yang X, Deng Y, Gu H, et al. Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes. *Mol Vis* [Internet]. 2011 cited 2022 Jul 4;17:3088. Available from: [/pmc/articles/PMC3233387/](https://pubmed.ncbi.nlm.nih.gov/21333387/)
- [39] Garcia JA, Lohmueller KE, Williams SM. Negative linkage disequilibrium between amino acid changing variants reveals interference among deleterious mutations in the human genome. *PLoS Genet* [Internet]. 2021 Jul 28 cited 2022 Oct 26;17(7):e1009676. Available from:
- [40] Wall JD, Pritchard JK. Haplotype blocks and linkage disequilibrium in the human genome. *Nat Rev Genet*. 2003 4:8 [Internet]. 2003 Aug 1 cited 2022 Aug 2;4 (8):587–597. Available from: <https://www.nature.com/articles/nrg1123>